Indeed, as stated above, there is an ongoing phase II clinical trial in ALS examining the effect of continuous intracerebroventricular VEGF delivery on motor function and survival using subcutaneous implanted pumps [65] (ClinicalTrials.gov NCT01384162, accessed on 7 March 2023). The gene discussed is VEGFA; the disease is amyotrophic lateral sclerosis.